MADRID, May 17, 2018 /PRNewswire/ --
During the Congress of the American Society of Clinical Oncology (ASCO) thatwill be held form the 1st to the 5th of June in Chicago (USA), PharmaMar will present the data obtained from various clinical studies of the molecules Yondelis ®,
(Logo: http://mma.prnewswire.com/media/624563/PharmaMar_Logo.jpg )
Two studies carried out with Yondelis® (trabectedin) will be presented, including an oral presentation by the French Sarcoma Group on the results of aprospective phase III study comparing trabectedin versus best supportive care in patients with soft tissue sarcoma. And the design of the phase I/II safety and efficacy study using the triple combination of trabectedin, ipilimumab and nivolumab for the first line treatment of soft tissue sarcoma.
PharmaMar will also have data for lurbinectedin (PM1183), presenting the clinical advances made in indications such as Ewing´s sarcoma, breast cancer and small-cell lung cancer, which is currently in a pivotal phase III clinical trial called ATLANTIS that should complete recruitment in Q3.
The studies that will be presented during the meeting are available at http://abstracts.asco.org
Studies highlighted at ASCO 2018
Lurbinectedin is a compound under clinical investigation which is an inhibitor of the RNA polymerase II enzyme which is essential for the transcription process. It's inhibition suppresses tumor growth, and results in tumor death. The antitumor efficacy of PM1183 is being investigated in various types of solid tumors.
Poster Board: #264. Saturday, June 2. 15:00 to 16:15. Hall A
Discussed at the Poster Discussion Sessuon on Satuday, June 2, from 15:00 to 16:15 at S404
Lead author: Vivek Subbiah, MD. The University of Texas MD Anderson Cancer Center
Poster board: #153. Saturday, June 2. 8:00 a.m. to 11:30 a.m. Hall A.
Lead author: Ahmad Awada, MD, PhD. Medical oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles
Poster board: #176. Sunday, June 3. 8:00 a.m to 11:30. Hall A.
Lead author: Jose Manuel Trigo Perez, MD. Hospital Virgen de la Victoria, Spain.
Poster board: #189b. Sunday, June 3. 8:00 a.m to 11:30. Hall A.
Lead author: Anna F. Farago, MD, PhD. Massachusetts General Hospital
Poster board: #377. Monday, June 4. 8:00 a.m. to 11:30. Hall A
Lead author: Shunji Takahashi, MD. Cancer Institute Hospital of JFCR
Trabectedin is a novel, multimodal, synthetically produced antitumor agent, originally derived from the sea squirt, Ecteinascidia turbinata. The drug exerts its activity by targeting the transcriptional machinery and impairing DNA repair.
Poster board: #258. Saturday, June 2. 15:00 to 16:15. Hall A
Lead author: Gurpreet Kapoor. Scientific Operations, LabConnect LLC.
Poster board: #289. Saturday, June 2. 15:00 to 16:15. Hall A
Lead author: Javier Martin Broto MD, PhD. Hospital Universitario Virgen del Rocio, Instituto de Investigación Biomédica, Universidad de Sevilla, Spain.
Poster board: #311. Saturday, June 2. 15:00 to 16:15. Hall A
Lead author: Roberta Sanfilippo, MD. Departamento de Oncología Médica, Fondazione IRCCS Istituto Nazionale dei Tumori
Poster board: #333b. Saturday, June 2. 15:00 to 16:15. Hall A
Lead author: Erlinda Maria Gordon, MD. Sarcoma Oncology Center
Oral sesión. Monday, June 4. 8:00 a.m. to 11:00. S100a
Lead author: Axel Le Cesne, MD. Gustave Roussy Cancer Campus
Poster board: #27. Monday, June 4. 8:00 to 11:30. Hall A
Discussed ta the poster discussion session on Monday, June 4, 15:00 to 16:15 at E450
Lead autor: Javier Gómez, PharmaMar
Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has other clinical-stage programs under development for several types of solid and hematological cancers, Zepsyre® (PM1183), plitidepsin, PM184 and PM14. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium, Austria and the United States. PharmaMar fully owns other companies: GENOMICA, a leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at http://www.pharmamar.com.
Media Relations (+34-638-79-62-15) and Investor Relations (+34 914444500), firstname.lastname@example.org
Subscribe to our Free Newsletters!
FDA approved elapegademase-lvlr injection for intramuscular use is used as an enzyme replacement ...
Armpit lumps and raised bumps in the armpits caused by infection, cysts and other types of ...
Bad eating habits will affect your health as well as your skin and make you look older than your ...View All